Activator and Type II Diabetics

Sponsor
Life University (Other)
Overall Status
Completed
CT.gov ID
NCT01782092
Collaborator
(none)
5
1
24
0.2

Study Details

Study Description

Brief Summary

The purpose of this study (15-subject prospective case series) is to examine the effects of the Activator Methods technique on decreasing A1c levels in patients with type II Diabetes Mellitus (aka adult-onset diabetes).

Condition or Disease Intervention/Treatment Phase
  • Other: Chiropractic Adjustment

Study Design

Study Type:
Observational
Actual Enrollment :
5 participants
Observational Model:
Case-Only
Time Perspective:
Prospective
Official Title:
Effect of Activator Methods Technique on Lowering A1c Levels in Type II Diabetics
Study Start Date :
Aug 1, 2012
Actual Primary Completion Date :
Aug 1, 2014
Actual Study Completion Date :
Aug 1, 2014

Arms and Interventions

Arm Intervention/Treatment
Chiropractic & Diabetes

All subjects will also receive chiropractic care and receive spinal adjustments as indicated by Basic and Intermediate Activator Methods Protocols, which uses a combination of provocative tests designed to elicit a relative change in leg length in the presence of subluxation. Special shoes designed for improved accuracy of leg length analysis will be used for all visits. The patients will be analyzed two times per week for the first month followed by once per week for the remainder of the study. The Activator Methods protocol will be followed for all visits by all doctors in accordance with the guidelines set forth by Activator Methods International, Ltd. The first four visits will be limited to Basic Protocol to allow the patients to become accustomed to the process.

Other: Chiropractic Adjustment
Chiropractic adjustments will be administered using Activator Methods Basic protocol

Outcome Measures

Primary Outcome Measures

  1. Lowered A1C Levels [6 months]

Eligibility Criteria

Criteria

Ages Eligible for Study:
30 Years to 60 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
Yes
Inclusion Criteria:
  • Subjects will be eligible to participate in the study if they are between the ages of 30-60 and are clinically diagnosed with Type II diabetes by their primary care providers or endocrinologists (diagnosis usually based on FPG > 126 mg/dL on two occasions).

  • Participants must have been diagnosed for at least one year and currently be under medical supervision for the disease.

  • They must also have an A1c measurement above 7%, which indicates less than optimal management of the disease.

Exclusion Criteria:
  • The study will exclude pregnant women;

  • those with co-morbidities affecting life expectancy (e.g. malignancy, CVD); uncontrolled hypertension (> 150/100 mmHg);

  • serious trauma (e.g. MVA) within the previous 12 months;

  • diagnosed bleeding/clotting disorders; those currently under chiropractic care or having contraindications to Activator care (e.g. vertebral fracture, infection, active inflammatory arthritis, severe osteoporosis).

The presence of these exclusions will be determined during the history and exam procedures. All female subjects will be asked to take precautions during their participation in the study to avoid becoming pregnant.

Contacts and Locations

Locations

Site City State Country Postal Code
1 Life University Marietta Georgia United States 30060

Sponsors and Collaborators

  • Life University

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Life University
ClinicalTrials.gov Identifier:
NCT01782092
Other Study ID Numbers:
  • I-009
First Posted:
Feb 1, 2013
Last Update Posted:
Apr 20, 2016
Last Verified:
Sep 1, 2015
Keywords provided by Life University
Additional relevant MeSH terms:

Study Results

No Results Posted as of Apr 20, 2016